Leading enterprise of recombinant protein drugs in China

Terminal coverage of domestic hospitals
7000
Third terminal
8900+HOUSEHOLDS
Pharmacy
4000+
Go Global
20+years
Country/region
40+
Digital Dynamization

Our Medicines

it explores the extensive application of biotechnology in thefield of general health, actively cultivates and incubates new industries, the world's leading industrial platforms such as animal vaccines, synthetic organisms and phage have been distributed，and is committed to becoming a leader in high-quality biopharmaceutics and serving global patients.

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China) Successfully Concluded

Recently, the "Innovation for the World, Exploring for the Future" 2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China), organized by Kexing Biopharm, was successfully concluded in Shanghai.

Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

On July 28 2024, Kexing Biopharm announced European Commission approval of Apexelsin®, the generic drug to Bristol Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel).

Kexing Biopharm Accelerates Global Commercialization with Successful INVIMA GMP Inspection

In a significant step forward for Kexing Biopharm, their product, Bevacizumab Injection, has recently undergone a successful Good Manufacturing Practice (GMP) inspection by the Colombian regulatory authority, INVIMA.

Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone

On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, approving its clinical trial application for GB08 injection solution developed independently by the company.

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countries. This is the fifth major breast cancer medication introduced by Kexing Biopharm, which further enriches its product portfolio for breast cancer treatment.

Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)

On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA) regulations.

Kexing Biopharm Teams Up with Qingfeng Pharma for the Global Market on Olaparib Tablets

Kexing Biopharm recently took an important step forward in cancer therapy. Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter referred to as "Qingfeng Pharma"), for the international commercialization of Olaparib Tablets.

Quality Control

Kexing Pharmaceutical has established a quality system that meets Chinese and international standards, systematically implementing the entire process of drug production, quality control, product release, storage, and transportation.

The quality system of Kexing Pharmaceutical includes a quality control system, a quality assurance system, and a validation system.

Quality standards: To minimize the risks of contamination, cross contamination, confusion, and errors during drug production, and ensure the continuous and stable production of drugs that meet the intended use and registration requirements.

Quality policy: sound system, honesty and trustworthiness, safety and effectiveness, continuous improvement